Management of Chronic Gastroparesis

Initial Management Approach

The American Gastroenterological Association recommends implementing low-fat, low-fiber meals with smaller, more frequent feedings (5-6 meals per day) for patients with chronic gastroparesis 1, 2
Patients with severe symptoms should replace solid food with liquids such as soups 1
Focus on foods with small particle size to improve key symptoms in patients with gastroparesis 3
Use complex carbohydrates and energy-dense liquids in small volumes for patients with gastroparesis 4
Avoid foods that delay gastric emptying (high-fat, high-fiber) in patients with chronic gastroparesis 1, 4

Pharmacologic Management

Metoclopramide (10 mg three times daily before meals) is the only FDA-approved medication for gastroparesis, according to the American College of Gastroenterology 1
Initial treatment with metoclopramide should be for at least 4 weeks to determine efficacy in diabetic gastroparesis patients 5
Be aware of the black box warning for tardive dyskinesia with metoclopramide use, although risk may be lower than previously estimated 5
Phenothiazines (prochlorperazine, trimethobenzamide, promethazine) can be used for nausea and vomiting in patients with gastroparesis 1
Serotonin (5-HT3) receptor antagonists can be used for refractory nausea in patients with gastroparesis 1
Erythromycin can be administered orally or intravenously for short-term use due to tachyphylaxis in patients with gastroparesis 1, 3
Domperidone (not FDA-approved in the US) can be used for patients with gastroparesis in Canada, Mexico, and Europe 1, 2

Management of Refractory Gastroparesis

Jejunostomy tube feeding can be considered for patients unable to maintain adequate oral intake 1, 4
Decompressing gastrostomy may be necessary in some cases of refractory gastroparesis 1
Botulinum toxin injection into the pyloric sphincter may provide modest temporary symptom improvement in selected patients with refractory gastroparesis 1
Gastric per-oral endoscopic myotomy (G-POEM) may be considered in severe cases of refractory gastroparesis 5

Monitoring and Follow-up

Evaluate effectiveness of therapy and adjust treatment as needed for patients with gastroparesis 5

Common Pitfalls to Avoid

Continuing metoclopramide beyond 12 weeks without careful reassessment (due to risk of tardive dyskinesia) is not recommended for patients with gastroparesis 3
Failing to recognize medication-induced gastroparesis (e.g., from opioids, GLP-1 agonists) can worsen symptoms in patients with gastroparesis 3, 5

Optimal Nutritional Management for Severe Gastroparesis

Nutritional Principles for Severe Gastroparesis

The American Diabetes Association recommends implementing 5-6 small meals daily to maximize nutritional intake while minimizing gastric distension, with a focus on low-fat, low-fiber foods that promote faster gastric emptying, as supported by the American Gastroenterological Association 6
The American Gastroenterological Association suggests prioritizing foods with small particle size to improve key symptoms, and avoiding foods that delay gastric emptying such as high-fat and high-fiber items 7

Meal Composition Guidelines

The European Society for Clinical Nutrition and Metabolism recommends a daily protein intake of 1.2-1.5 g/kg/day to address malnutrition, which translates to 60-75g daily for a 50kg patient 8
The American Society for Parenteral and Enteral Nutrition suggests aiming for 25-30 kcal/kg/day, or 1250-1500 kcal daily, to promote weight restoration in patients with severe gastroparesis 9
The European Society for Clinical Nutrition and Metabolism advises limiting fat intake to less than 30% of total calories to promote gastric emptying 10

Additional Nutritional Considerations

The American Gastroenterological Association recommends monitoring for micronutrient deficiencies, especially vitamin B12, vitamin D, iron, and calcium, and considering oral nutritional supplements between meals to increase caloric and protein intake 10
The American Gastroenterological Association suggests considering jejunal tube feeding if oral intake remains inadequate despite these measures, and avoiding medications that can worsen gastroparesis symptoms, such as opioids and GLP-1 agonists 7

Monitoring Recommendations

The European Association for the Study of the Liver recommends weekly weight measurements to assess nutritional adequacy, and regular assessment of mid-arm circumference to monitor for malnutrition 11
The European Association for the Study of the Liver suggests evaluating for sarcopenia, which may be masked by fluid retention, and monitoring for signs of micronutrient deficiencies 11
The American Society for Parenteral and Enteral Nutrition advises monitoring for signs of micronutrient deficiencies, especially vitamin B12, vitamin D, iron, and calcium 10

Optimal Dietary Management for Severe Gastroparesis

Introduction to Dietary Principles

The American College of Cardiology suggests avoiding lying down for at least 2 hours after eating to reduce symptoms of gastroparesis 12
The American Diabetes Association recommends avoiding medications that can worsen gastroparesis symptoms, such as opioids and GLP-1 agonists, as stated in Diabetes Care 13

Medication Considerations

Metoclopramide may be considered for symptom management, but use should be limited to 12 weeks due to risk of tardive dyskinesia, as recommended by the Diabetes Care 13
Antiemetics like ondansetron or promethazine may help control nausea, according to the Journal of the American College of Cardiology 12

Tube Feeding Candidacy in Gastroparesis with Inadequate Nutrition

Direct Recommendation

The American Society for Parenteral and Enteral Nutrition recommends tube feeding via jejunostomy if oral intake remains below 50-60% of energy requirements for more than 10 days despite dietary modifications and medical therapy 14, 15

Clinical Decision Algorithm

Step 1: Assess Current Nutritional Status and Intake Duration

Initiate tube feeding if oral intake is <60% of caloric requirements for >10 days despite adequate dietary support and oral nutritional supplements, as recommended by the American Society for Parenteral and Enteral Nutrition 14, 15
Document specific nutritional risk factors, including weight loss >10-15% within 6 months, BMI <18.5 kg/m², and serum albumin <30 g/L, according to the American Society for Parenteral and Enteral Nutrition 14

Step 3: Select Appropriate Tube Feeding Route

The American Gastroenterological Association recommends jejunostomy tube feeding as the preferred route for gastroparesis patients because it bypasses the dysfunctional stomach entirely 16, 15
Use a nasojejunal tube for anticipated duration <4 weeks or trial period, as suggested by the American Society for Parenteral and Enteral Nutrition 15
Use percutaneous endoscopic jejunostomy (PEJ) for anticipated duration >4 weeks or if nasojejunal feeding is not tolerated, according to the American Society for Parenteral and Enteral Nutrition 16, 15
Avoid gastrostomy tubes (PEG) in gastroparesis as they do not bypass the gastric emptying problem, as recommended by the American Gastroenterological Association 16

Step 4: Initiate Feeding Protocol

Start with continuous feeding at low flow rates due to limited intestinal tolerance, beginning at 10-20 mL/hour, as recommended by the American Society for Parenteral and Enteral Nutrition 14
Gradually advance over 5-7 days to reach target intake, according to the American Society for Parenteral and Enteral Nutrition 14
Use standard whole protein formula initially, as suggested by the American Society for Parenteral and Enteral Nutrition 14

Step 6: Continue Oral Intake as Tolerated

Reassess weekly during first month, then monthly thereafter, and attempt to wean tube feeding as oral intake improves, as recommended by the American Society for Parenteral and Enteral Nutrition 15

Key Clinical Pitfalls to Avoid

Do not use gastrostomy (PEG) tubes in gastroparesis patients as they deliver nutrition into the dysfunctional stomach and will not bypass the emptying problem, as recommended by the American Gastroenterological Association 16
Do not delay tube feeding beyond 10 days of inadequate intake in patients with documented gastroparesis, as malnutrition significantly worsens outcomes, according to the American Society for Parenteral and Enteral Nutrition 14, 15

When Parenteral Nutrition is Indicated

Parenteral nutrition should be reserved as a last resort only when jejunal feeding fails or is contraindicated, as recommended by the American Society for Parenteral and Enteral Nutrition 14
Use only for short-term when hydration and nutritional state cannot be maintained enterally, and be aware of higher complication rates including catheter-related sepsis, as noted by the American Society for Parenteral and Enteral Nutrition 17

Contraindications to Tube Feeding

Absolute contraindications include intestinal obstruction or ileus, severe shock, and intestinal ischemia, as stated by the American Society for Parenteral and Enteral Nutrition 14

Management of Diabetic Gastroparesis

Advanced Interventions for Medically Refractory Cases

Gastric electrical stimulation (GES) could be an option for gastroparesis patients with refractory/intractable nausea and vomiting who have failed standard therapy, are not on opioids, and do not have abdominal pain as the predominant symptom, according to the American Gastroenterological Association 18
Gastric per-oral endoscopic myotomy (G-POEM) may be considered in severe, refractory cases, but should only be performed at tertiary care centers using a team approach of experts with extensive experience, as recommended by the American Gastroenterological Association 18
G-POEM has the theoretical potential to induce dumping syndrome, which has a deleterious effect on food tolerance and quality of life, as noted by the American Gastroenterological Association 18
Available data argue against use of intrapyloric botulinum toxin in refractory gastroparesis, except in clinical trials, according to the American Gastroenterological Association 18
Transpyloric stent placement should be considered investigational in refractory gastroparesis for the lack of data from prospective, sham-controlled trials and concerns over stent migration, as stated by the American Gastroenterological Association 18

Treatment of Gastroparesis

Pharmacologic Treatment

The American Gastroenterological Association recommends considering domperidone as a treatment option for gastroparesis, if available, as evidenced by studies published in Gastroenterology 19
The American Gastroenterological Association suggests that 5-HT3 receptor antagonists, such as ondansetron, can be used as first-line antiemetic therapy for refractory nausea in patients with gastroparesis, as reported in Gastroenterology 19

Advanced Interventions

The American College of Gastroenterology recommends considering gastric electrical stimulation (GES) for refractory nausea and vomiting in patients with gastroparesis when standard therapy fails, as published in Clinical Gastroenterology and Hepatology 20
The American College of Gastroenterology suggests that gastric per-oral endoscopic myotomy (G-POEM) may be considered in severe cases of gastroparesis, but only at tertiary care centers with extensive experience, as reported in Clinical Gastroenterology and Hepatology 20

Management of Severe Gastroparesis in Patients with Seizure Disorders

Drug Safety Considerations

Metoclopramide, the only FDA‑approved gastroparesis medication, is contraindicated in individuals with active seizure disorders because it lowers the seizure threshold and can precipitate seizures. [21][22]23

Dietary Management

Initiate aggressive dietary modification: prescribe 5–6 small meals per day of low‑fat, low‑fiber foods with fine particle size to promote gastric emptying without pharmacologic therapy. 21

Medication Adjustments (Glycemic Control & Motility‑Impeding Drugs)

In patients with diabetes, discontinue or reduce GLP‑1 receptor agonists (e.g., semaglutide, dulaglutide, liraglutide) and pramlintide, as these agents markedly delay gastric emptying. [21][22]23
Withdraw other medications that impair gastrointestinal motility—including opioids, anticholinergics, and tricyclic antidepressants—to improve gastric transit. [21][22]23

Seizure‑Safe Antiemetic Options

Phenothiazine antiemetics (e.g., prochlorperazine 5–10 mg, promethazine) may be used for breakthrough nausea, but clinicians should be aware of a modest risk of extrapyramidal side effects. 21

Seizure‑Safe Prokinetic Agents

Erythromycin 125 mg taken three times daily before meals is the safest prokinetic option for patients with seizures; however, its efficacy diminishes after 2–4 weeks due to tachyphylaxis. [21][22]23
Domperidone (where available outside the United States) is an excellent alternative because it does not cross the blood‑brain barrier and does not lower seizure threshold; QTc interval monitoring is required. [21][23]

Advanced Therapies for Refractory Cases

Gastric electrical stimulation (GES) may be considered for patients with refractory nausea and vomiting when standard medical therapy fails; the evidence indicates variable efficacy. [21][22]23